Themis Bioscience

29 articles with Themis Bioscience

• Merck Completes Acquisition of Themis

  6/19/2020

  Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. The U.S. Federal Trade Commission has granted early termination of the waiting period under t

• Merck to Acquire Themis

  5/26/2020

  Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur

• 

  Merck Takes 3 Major Shots at COVID-19: Themis, IAVI and Ridgeback Bio

  5/26/2020

  Merck has largely stayed out of the COVID-19 battle, but exploded into it with three major deals and collaborations today.

• Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

  5/11/2020

  ABL applies its expertise in custom manufacturing virus-based therapeutics to accelerate the Institut Pasteur and Themis' coalition COVID-19 vaccine development   [11-May-2020]   VIENNA , and STRASBOURG, France , May 11, 2020 /PRNewswire/ --  Themis , a clinical-stage biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, and

• 

  BioSpace Global Roundup, Oct. 31

  10/31/2019

  Companies from across the globe share updates to their businesses and pipelines.

• Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine

  10/29/2019

  Coalition for Epidemic Preparedness Innovations (CEPI) partnership will support Themis’ development and manufacturing of vaccine candidate

• 

  BioSpace Global Roundup, Oct. 3

  10/3/2019

  Companies from across the globe share information on their business and pipelines.

• Themis Bioscience and ZIKAVAX Consortium Announce Initiation of Phase 1 Zika Vaccine Trial

  10/1/2019

  European Union’s Horizon 2020 Program Funding Underwrites Second-Generation Zika Vaccine Candidate Development

• Themis Raises EUR 40 Million in Series D Financing Round Backed by US/EU Consortium to Support Pivotal Study and Expand Clinical Pipeline

  9/18/2019

  Themis well-funded through completion of Chikungunya Phase 3 program

• Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates

  8/22/2019

  Themis Bioscience announced a research collaboration and exclusive license agreement with MSD for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform.

• 

  BioSpace Global Roundup, June 6

  6/6/2019

  Companies from across the globe share updates on their pipelines and growth strategies.

• CEPI Awards up to US$21 Million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development

  6/4/2019

  Funding will support this registration study and rapid global availability of the vaccine against Chikungunya

• 

  BioSpace's Global Biopharma Roundup: Feb. 28

  2/28/2019

  BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.

• Themis Bioscience Receives FDA Fast Track Designation for Chikungunya Vaccine Candidate

  2/25/2019

  Themis Bioscience announced that the United States Food and Drug Administration has granted fast track designation to the Company’s lead vaccine candidate for the prevention of Chikungunya, a debilitating disease with global outbreak potential.

• Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet

  11/5/2018

  MV-CHIK met the primary endpoint, eliciting a potent immune response as measured by induction of neutralizing antibodies against Chikungunya, in all treatment groups

• Themis Bioscience Announces Exclusive Licensing Agreement with Max-Planck-Innovation to Develop and Commercialize Oncolytic Virotherapies

  10/11/2018

  Themis to expand measles vector immunomodulation portfolio into oncology indications

• Themis Receives EMA PRIME Designation for Chikungunya Vaccine

  6/11/2018

  The PRIME scheme is designed to provide enhanced regulatory support for the development of medicines that target an unmet medical need.

• CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS

  3/7/2018

  First major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases.

• Themis Establishes Scientific Advisory Board of Experts in Virology and Vaccine Development

  2/26/2018

  The purpose of the SAB will be to advise Themis as it continues to develop its pipeline of urgently needed vaccines and immune system activation approaches.

• Themis to Present Phase II Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting

  11/6/2017

  The data will be presented today for the first time at the Annual Meeting of the ASTMH in Baltimore, MA, USA.